Mineralocorticoid Receptor Antagonists

Mineralocorticoid Receptor Antagonists

The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to...

Full description

Bibliographic Details
Main Authors: Ilaria Spoletini, Giuseppe MC Rosano
Format: Article
Language:English
Published: Barcaray International 2019-01-01
Series:International Cardiovascular Forum Journal
Subjects:
heart failure
mineralocorticoid receptor antagonists
Online Access:https://icfjournal.org/index.php/icfj/article/view/603/pdf
id doaj-848580effa6e45b8b6b1356181b43207
record_format Article
spelling doaj-848580effa6e45b8b6b1356181b432072020-11-25T03:57:04ZengBarcaray InternationalInternational Cardiovascular Forum Journal2410-26362409-34242019-01-01173436https://doi.org/10.17987/icfj.v17i0.603Mineralocorticoid Receptor AntagonistsIlaria Spoletini0Giuseppe MC Rosano1IRCCS San Raffaele Pisana, ItalyCentre for Clinical & Basic Research IRCCS San Raffaele Pisana, via della Pisana, 235, 00163 Rome, ItalyThe role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845. These newer agents aim to optimise the benefits of MRAs and reduce their side-effects, especially hyperkalaemia.https://icfjournal.org/index.php/icfj/article/view/603/pdfheart failuremineralocorticoid receptor antagonists
collection DOAJ
language English
format Article
sources DOAJ
author Ilaria Spoletini
Giuseppe MC Rosano
spellingShingle Ilaria Spoletini
Giuseppe MC Rosano
Mineralocorticoid Receptor Antagonists
International Cardiovascular Forum Journal
heart failure
mineralocorticoid receptor antagonists
author_facet Ilaria Spoletini
Giuseppe MC Rosano
author_sort Ilaria Spoletini
title Mineralocorticoid Receptor Antagonists
title_short Mineralocorticoid Receptor Antagonists
title_full Mineralocorticoid Receptor Antagonists
title_fullStr Mineralocorticoid Receptor Antagonists
title_full_unstemmed Mineralocorticoid Receptor Antagonists
title_sort mineralocorticoid receptor antagonists
publisher Barcaray International
series International Cardiovascular Forum Journal
issn 2410-2636
2409-3424
publishDate 2019-01-01
description The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is wellrecognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spironolactone and eplerenone, have been proven to reduce mortality in HFrEF. In patients with HFpEF, the TOPCAT trial found no significant benefits of spironolactone on cardiovascular outcomes. In order to overcome the limitations of existing steroidal MRAs, novel MRAs have been recently developed, finerenone and PF-03882845. These newer agents aim to optimise the benefits of MRAs and reduce their side-effects, especially hyperkalaemia.
topic heart failure
mineralocorticoid receptor antagonists
url https://icfjournal.org/index.php/icfj/article/view/603/pdf
work_keys_str_mv AT ilariaspoletini mineralocorticoidreceptorantagonists
AT giuseppemcrosano mineralocorticoidreceptorantagonists
_version_ 1724462168429035520

Similar Items